Trial reportBlood2017
Neutral tumor evolution in myeloma is associated with poor prognosis.
Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics.Blood cancer journal · 2020Trial
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- The evolutionary theory of cancer: challenges and potential solutions.Nature reviews. Cancer · 2024Review
- Frequency-dependent selection of neoantigens fosters tumor immune escape and predicts immunotherapy response.Communications biology · 2024Article
- Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome.Cell reports. Medicine · 2023Article
- Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming.Molecular cancer · 2022Article
- Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing.Biomedicines · 2022Article
- Review
- Clonal Evolution of Multiple Myeloma-Clinical and Diagnostic Implications.Diagnostics (Basel, Switzerland) · 2021Review
- Article
- Article
- RGB-Marking to Identify Patterns of Selection and Neutral Evolution in Human Osteosarcoma Models.Cancers · 2021Article
- Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma.Cancers · 2021Review
- Branching clonal evolution patterns predominate mutational landscape in multiple myeloma.American journal of cancer research · 2021Article
- Molecular basis of clonal evolution in multiple myeloma.International journal of hematology · 2020Review
- Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.Leukemia · 2020Article
- Resolving genetic heterogeneity in cancer.Nature reviews. Genetics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Recent studies suggest that the evolutionary history of a cancer is important in forecasting clinical outlook. To gain insight into the clonal dynamics of multiple myeloma (MM) and its possible influence on patient outcomes, we analyzed whole exome sequencing tumor data for 333 patients from Myeloma XI, a UK phase 3 trial and 434 patients from the CoMMpass study, all of which had received immunomodulatory drug (IMiD) therapy. By analyzing mutant allele frequency distributions in tumors, we found that 17% to 20% of MM is under neutral evolutionary dynamics. These tumors are associated with poorer patient survival in nonintensively treated patients, which is consistent with the reduced therapeutic efficacy of microenvironment-modulating IMiDs. Our findings provide evidence that knowledge of the evolutionary history of MM has relevance for predicting patient outcomes and personalizing therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.